Advertisement
Screener

ProPhase Labs, Inc. (PRPH) Cash Provided by (Used in) Financing Activities, Discontinued Operations

ProPhase Labs, Inc. Cash Provided by (Used in) Financing Activities, Discontinued Operations

ProPhase Labs, Inc. (PRPH) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of -$35.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.

Financial Statements › Cash Flow › Financing Activities

us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2026-08-19

  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-09-30 was $0.00.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-06-30 was $0.00.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2025-03-31 was -$35.00K.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for fiscal 2025 was -$35.00K, a 103.58% decline from fiscal 2024.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for fiscal 2024 was $978.00K, a 66.55% decline from fiscal 2023.
  • ProPhase Labs, Inc. cash provided by (used in) financing activities, discontinued operations for fiscal 2023 was $2.92M.
Period endCash Provided by (Used in) Financing Activities, Discontinued Operations 3 monthCash Provided by (Used in) Financing Activities, Discontinued Operations 6 monthCash Provided by (Used in) Financing Activities, Discontinued Operations 9 monthCash Provided by (Used in) Financing Activities, Discontinued Operations 12 month
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01
$0.00
derived: sum of 2 quarters · filed 2026-06-01
$0.00
derived: sum of 3 quarters · filed 2026-08-19
-$35.00K
10-K · filed 2026-06-01
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$0.00
derived: sum of 2 quarters · filed 2026-08-19
-$35.00K
10-Q · filed 2025-11-19
$959.00K
derived: sum of 4 quarters · filed 2026-08-19
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19
-$35.00K
10-Q · filed 2026-08-19
$959.00K
derived: sum of 3 quarters · filed 2026-08-19
$953.00K
derived: sum of 4 quarters · filed 2026-08-19
2025-03-31-$35.00K
10-Q/A · filed 2026-07-09
$959.00K
derived: sum of 2 quarters · filed 2026-07-09
$953.00K
derived: sum of 3 quarters · filed 2026-07-09
$947.00K
derived: sum of 4 quarters · filed 2026-07-09
2024-12-31$994.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01
$988.00K
derived: sum of 2 quarters · filed 2026-06-01
$982.00K
derived: sum of 3 quarters · filed 2026-06-01
$978.00K
10-K · filed 2026-06-01
2024-09-30-$6.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
-$12.00K
derived: sum of 2 quarters · filed 2025-11-19
-$16.00K
10-Q · filed 2025-11-19
2024-06-30-$6.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$10.00K
10-Q · filed 2025-08-13
2024-03-31-$4.00K
10-Q · filed 2025-05-20
2023-12-31$2.92M
10-K · filed 2025-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Pulmatrix, Inc. (PULM)United States$0.006B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26